Kimberly-Clark (NYSE:KMB) has received mixed analyst ratings over the past three months, with a recent shift towards a more bullish outlook. The average 12-month price target is now $125.00, a slight decrease from the previous $127.50. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting varied perceptions of the company's market position. Kimberly-Clark, known for its personal care and consumer tissue products, shows a positive revenue trend but lags in revenue growth compared to industry peers. Its financials indicate strong profitability and effective cost management, though it faces challenges in efficiently using equity capital.